« Back to news

Chesterford Research Park attracts leader in formulation technology innovation, Arecor, to the Park

Chesterford Research Park attracts leader in formulation technology innovation, Arecor, to the Park

 

Arecor confirms move to Chesterford Research Park  

Chesterford Research Park is delighted to confirm that Arecor will be moving to the Park in October this year. The biopharmaceutical company is taking a five year lease within an existing 5,300 sq ft Park building and will move in after refurbishment works are complete.

Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform, Arestat™.  Arecor is leveraging Arestat™ to develop a portfolio of proprietary products to enable improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.  These products will enable next-generation technology and, most importantly, improve quality of life for those with diabetes.

Next-generation device technology such as wearable, continuous administration patch pumps and implants are critical future developments for people living with diabetes. By improving glycemic control and compliance, adverse states such as hypoglycaemia and diabetic ketoacidosis (DKA) can be reduced, as can overall complications and mortality.  Arecor is in a unique position to leverage its innovative formulation approach to enable significant advancements in this area by delivering products such as:

  • highly concentrated formulations of insulin to enable the miniaturisation of wearable devices,
  • ultra-rapid acting insulins which will offer a vastly superior meal-time insulin to those currently available on the market, both from a convenience (dosing at or after meal-time) and glycemic control perspective and;
  • a ready-to-use emergency glucagon pen to treat severe hypoglycaemia, which is currently a critical unmet need.   


In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.  Many proteins and peptides are too unstable in liquid form to develop ready-to-use drugs, or are unstable at high concentrations.  Arecor has overcome these challenges to significantly enhance the delivery of therapeutic medicines to patients.

Dr Sarah Howell, CEO, Arecor commented of the move: “Arecor is experiencing significant growth and we required enhanced facilities that could meet our expansion requirements, both today and well into the future. We selected Chesterford because of the quality of innovative companies already located here, the Park’s location within the Cambridge cluster and the excellent central facilities.  Attracting top talent as we continue to grow is key to our future success and we feel that Chesterford is the ideal location from which we can continue to forge ahead.”

As Arecor’s proprietary diabetes product moves into clinical trials and the organisation’s strategic partnerships with major pharmaceutical and biotech companies continue to expand, the organisation expects to experience significant growth.  Chesterford’s range of accommodation options ideally cater for occupier growth – from managed office space and individual R&D suites to bespoke build pre-lets, there are multiple options available to occupiers as their requirements change and grow.

INVEST Essex, Essex County Council’s inward investment team, worked with Arecor on their choice of site and introduced them to Uttlesford District Council who were able to provide support to Arecor with their Business Development Rate Relief Scheme.

Cllr Kevin Bentley, Deputy Leader of Essex County Council, said: “Essex is home to a great many innovative, cutting edge companies and we are pleased to welcome Arecor to the county. INVEST Essex, our inward investment team at Essex County Council, has been instrumental in helping the company with their choice of site and supporting them in making this major investment in Essex.

“This is the latest investment in the county by a high-tech firm and one that we welcome. Essex means business and it is pleasing to see more and more companies recognise this and invest in the county.”

Chesterford Research Park’s low-density development, set within 250 acres of impressive parkland, offers not only ultra modern and energy efficient laboratory and office space, but also central ‘hub’ facilities within The Nucleus building - which includes a restaurant, café bar, health and fitness centre and meeting and conferencing space. The Park provides an innovative, flexible and future proofed environment for both established and early stage biotechnology and pharmaceutical research and development companies. Arecor joins major players such as AstraZeneca, Illumina Inc and Domainex, who have also chosen Chesterford as the base from which to advance their research and development.

For further information regarding occupancy options please contact the joint agents for Chesterford Research Park – William Clarke at Savills (01223) 347294 or Michael Jones at Dodson Jones (01223) 358114.

 

 

Share this: